Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 16/20 | 0.74 |
| ▸ | AURKA | O14965 | 15/20 | 0.74 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240362 | 0.88 | AURKB (0.88) | AURKBAURKACHEK1TTKLCK | |
| SCHEMBL14538650 | 0.87 | AURKA (0.72) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL12404514 | 0.87 | AURKB (0.71) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL12404508 | 0.86 | AURKA (0.71) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL8246690 | 0.86 | AURKA (0.70) | AURKBAURKACHEK1TTK | |
| SCHEMBL12404511 | 0.85 | AURKA (1.00) | AURKBAURKACHEK1IRAK4 | |
| SCHEMBL8241796 | 0.84 | AURKB (1.00) | AURKBAURKACHEK1LCK | |
| SCHEMBL12404510 | 0.84 | AURKA (0.67) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL14507329 | 0.83 | AURKA (0.66) | AURKBAURKACHEK1LCKKDR | |
| SCHEMBL12404517 | 0.83 | AURKA (0.68) | AURKBAURKACHEK1LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |